Enzyme immunoassay for the quantitative determination of Durvalumab (Imfinzi®) in serum and plasma.
This kit has been especially developed for the quantitative determination of Durvalumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Durvalumab Drug Bank Accession Number is DB11714.
Durvalumab is an antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Durvalumab blocks programmed death-ligand 1 (PD-L1) to promote normal immune responses that attack tumour cells. . Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
| Required Volume (µl) | 10 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 6 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
Reviews
There are no reviews yet.